
Paratek Pharmaceuticals PRTK
Paratek Pharmaceuticals Accounts Receivables | PRTK
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.7 M | 29.4 M | 11.9 M | 8.48 M | 41 K | 5.04 M | - | 745 K | 4.43 M | 243 K | 168 K | 288 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.7 M | 41 K | 12.3 M |
Quarterly Accounts Receivables Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.3 M | 36.9 M | 74.7 M | 29.4 M | 28.5 M | 24.7 M | 29.4 M | 21.9 M | 55.6 M | 15.9 M | 11.9 M | 13 M | 8.66 M | 10.9 M | 8.48 M | 3.98 M | 2.56 M | 2.2 M | 41 K | 22 K | 19 K | 50 K | 5.04 M | 5.04 M | 5.04 M | 5.04 M | - | 230 K | 85 K | 488 K | 745 K | 270 K | 496 K | 391 K | 4.43 M | 4.43 M | 4.43 M | 4.43 M | 243 K | - | - | - | 168 K | - | - | - | 288 K | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 74.7 M | 19 K | 11.6 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
InMed Pharmaceuticals
INM
|
1.95 M | $ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
308 M | $ 12.36 | -9.55 % | $ 799 M | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
831 M | $ 228.26 | -3.46 % | $ 13.9 B | ||
|
Johnson & Johnson
JNJ
|
17.2 B | $ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
5.55 M | $ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
2.4 M | $ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
10 M | $ 1.0 | -5.17 % | $ 87.1 M | ||
|
Compugen Ltd.
CGEN
|
61 M | $ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
17.8 M | $ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
25 K | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
2.02 M | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Lineage Cell Therapeutics
LCTX
|
891 K | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
643 K | $ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
17.8 B | $ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
211 M | $ 24.73 | -1.9 % | $ 783 M | ||
|
Curis
CRIS
|
3.35 M | $ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
171 M | $ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
700 K | $ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
13.2 M | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
1 K | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
123 M | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
38.4 M | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
1.09 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
11.8 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
184 M | $ 195.25 | -2.05 % | $ 76 B | ||
|
Novartis AG
NVS
|
12 M | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
53.7 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
2.03 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
Geron Corporation
GERN
|
37 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Phathom Pharmaceuticals
PHAT
|
78.1 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
34 M | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
12.2 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Liquidia Corporation
LQDA
|
54.1 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
2 M | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
6.01 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
182 M | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
928 K | $ 1.24 | -12.34 % | $ 4.53 B |